Content
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Article By:
ChinaBio® Today
Read
Saturday, January 14, 2023 2:20 PM EDT
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch Exkivity in China.
Fairness And The Tight Labor Market
Article By:
Bill Conerly
Read
Thursday, January 12, 2023 9:22 AM EDT
Many employees may feel unfairly treated, but that doesn’t have to be the case. Good management and sharing facts can avert that sense is mistreatment.
Is Bitcoin A Commodity?
Video By:
George Dagnino
Watch
Thursday, January 12, 2023 4:30 AM EDT
Is Bitcoin a commodity? This video shows you the relationship between Bitcoin and commodities like copper and lumber. See how our proprietary business cycle indicator is a valuable tool to predict turning points and trends of Bitcoin and commodities.
In this video: WOOD, JJC (RETIRED), BITCOMP
Binance Addresses Reported Failure To Properly Back BUSD
Article By:
The Tokenist
Read
Wednesday, January 11, 2023 5:44 AM EDT
After it was reported that BUSD was undercollateralized by as much as $1 billion in the past, Binance offered its explanation for the previous discrepancies—and detailed how it has addressed them.
In this article: BNB-X
NFIB Small Business Survey: Optimism Declines In December
Article By:
Jill Mislinski
Read
Tuesday, January 10, 2023 9:31 AM EDT
The headline number for December came in at 89.8, down 2.1 from the previous month. The index is at the 7th percentile in this series.
ISM Services Plunges 6.9 Points Into Contraction, Another Recession Warning
Article By:
Mish Shedlock
Read
Sunday, January 8, 2023 4:47 AM EDT
Economists missed the mark badly in estimating ISM services which plunged into contraction.
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
Article By:
ChinaBio® Today
Read
Saturday, January 7, 2023 2:20 PM EDT
WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to $1.46 billion in milestones, plus royalties.
9 Technology Trends For 2023: Explained
Article By:
Kalen Bruce
Read
Saturday, January 7, 2023 10:01 AM EDT
Due to the quick changes taking place around the globe, the digital environment is changing. The state of technology has advanced significantly.
Investing In 2023 - The Crucial Events Driving The Markets
Video By:
George Dagnino
Watch
Tuesday, January 3, 2023 6:15 AM EDT
Business decisions drive the business cycle. These decisions will impact the markets in 2023 and beyond.
What’s In Store For Banking In 2023?
Article By:
Chris Skinner
Read
Tuesday, January 3, 2023 3:27 AM EDT
2023 will call for bankers to reset their goals for search, chatbots, virtual assistants, and other automated features. Going forward, automation will be measured by its ability to deliver more satisfying digital experiences.
Top Picks For 2023: Catalyst Pharmaceuticals
Article By:
MoneyShow.com
Read
Monday, January 2, 2023 12:30 PM EDT
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top pick for 2023.
Inflation Rates May Stay Higher Than The Market Thinks In 2023
Video By:
Michael J. Kramer
Watch
Monday, January 2, 2023 7:26 AM EDT
The market expects the inflation rate to fall sharply in 2023, but the velocity of money suggests that inflation is more than likely to stay high.
In this video: WMT
Regulators Will End The Beauty Contest Of Fund Names To Avoid Greenwashing
Article By:
Lipper Alpha Insight
Read
Monday, January 2, 2023 4:15 AM EDT
In the good old days, the name of a mutual fund gave investors a clear hint about the investment objective and/or strategy of the fund. Unfortunately, these days are over, and fund names have become another tool in the toolbox for product marketing.
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
Article By:
ChinaBio® Today
Read
Saturday, December 31, 2022 2:30 PM EDT
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by themselves.
Top Picks For 2023: Celsius Holdings
Article By:
MoneyShow.com
Read
Saturday, December 31, 2022 1:59 PM EDT
If you want a growth stock that delivers energy, look no further than Celsius, which competes with Red Bull and Monster Beverage in the energy/performance drink market.